Valuation of the economic benefits of human papillomavirus vaccine in Taiwan

Value in Health

Volumn 12, Issue SUPPL. 3, 2009, Pages

  Liao, Chih Hsien ^a   Liu, Jin Tan ^b   Pwu, Raoh Fang ^a,c   You, San Lin ^d   Chow, Ines ^a   Tang, Chao Hsiun ^a,e  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c Center for Drug Evaluation   (Taiwan)

^d GENOMICS RESEARCH CENTER   (Taiwan)

^e TAIPEI MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Contingent valuation method; Human papillomavirus vaccine; Value of a statistical life; Willingness to pay

Indexed keywords

WART VIRUS VACCINE;

ADULT; ARTICLE; CANCER PREVENTION; CONTINGENT VALUATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MONEY; PATIENT ATTITUDE; PRIORITY JOURNAL; TAIWAN; UTERINE CERVIX CANCER; VACCINATION;

EID: 72149105315     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1111/j.1524-4733.2009.00632.x     Document Type: Article

References (27)

1. Bureau of Health Promotion. Cancer Registration System Annual Report 2006. Taipei : Bureau of Health Promotion, Department of Health, ROC of Republic of Taiwan, 2007.
2. Bureau of Health Promotion. Pap Smear Screening Registry System Annual Report 2007. Taipei : Bureau of Health Promotion, Department of Health, ROC of Republic of Taiwan, 2008.
3. WHO/ICO Information Centre on HPV and Cervical Cancer. HPV and cervical cancer in the World: 2007 report. Vaccine 2007 25 : C1 26.
4. Koong SL, Yen AM, Chen TH. Efficacy and cost-effectiveness of nationwide cervical cancer screening in Taiwan. J Med Screen 2006 13 (Suppl. 1 S44 7.
5. Munoz N, Bosch FX, de Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003 348 : 518 527. (Pubitemid 36159887)
6. Kim D, Canh do G, Poulos C, et al. Private demand for cholera vaccines in Hue, Vietnam. Value Health 2008 11 : 119 128.
7. Yen ZS, Chang CJ, Chen SY, et al. How much would you be willing to pay for preventing a new dangerous infectious disease: a willingness-to-pay study in medical personnel working in the emergency department. Am J Infect Control 2007 35 : 516 520.
8. Liu JT, Hammitt JK, Wang JD, et al. Valuation of the risk of SARS in Taiwan. Health Econ 2005 14 : 83 91.
9. Hsu HC, Lin RS, Tung TH, et al. Cost-benefit analysis of routine childhood vaccination against chickenpox in Taiwan: decision from different perspectives. Vaccine 2003 21 : 3982 3987.
10. Liu JT, Hammitt JK, Wang JD, et al. Mother's willingness to pay for her own and her child's health: a contingent valuation study in Taiwan. Health Econ 2000 9 : 319 326.
11. Prosser LA, Ray GT, O'Brien M, et al. Preferences and willingness to pay for health states prevented by pneumococcal conjugate vaccine. Pediatrics 2004 113 : 283 290.
12. Viscusi WK, Aldy JE. The value of a statistical life: a critical review of market estimates throughout the world. J Risk Uncertain 2003 27 : 5 76.
13. Kenkel D. Using estimates of the value of a statistical life in evaluating consumer policy regulations. J Cons Pol 2004 26 : 1 21.
14. Smith RD. Construction of the contingent valuation market in health care: a critical assessment. Health Econ 2003 12 : 609 628.
15. Smith RD. It's not just what you do, it's the way that you do it: the effect of different payment card formats and survey administration on willingness to pay for health gain. Health Econ 2006 15 : 281 293.
16. Frew EJ, Whynes DK, Wolstenholme JL. Eliciting willingness to pay: comparing closed-ended with open-ended and payment scale formats. Med Decis Making 2003 23 : 150 159.
17. Smith RD. The discrete-choice willingness-to-pay question format in health economics: should we adopt environmental guidelines? Med Decis Making 2000 20 : 194 206.
18. Klose T. The contingent valuation method in health care. Health Policy 1999 47 : 97 123.
19. Ready RC, Buzby JC, Hu D. Differences between continuous and discrete contingent value estimates. Land Econ 1996 72 : 397 411.
20. Stewart JM, O'Shea E, Donaldson C, et al. Do ordering effects matter in willingness-to-pay studies of health care? J Health Econ 2002 21 : 585 599.
21. Lee GM, Salomon JA, LeBaron CW, et al. Health-state valuations for pertussis: methods for valuing short-term health states. Health Qual Life Outcomes 2005 3 : 1 14.
22. Tang CH, Liu JT, Chang CW, et al. Willingness to pay for drug abuse treatment: results from a contingent valuation study in Taiwan. Health Policy 2007 82 : 251 262.
23. Prosser LA, Bridges CB, Uyeki TM, et al. Values for preventing influenza-related morbidity and vaccine adverse events in children. Health Qual Life Outcomes 2005 3 : 1 9.
24. Hammitt JK, Liu J-T. Effects of disease type and latency on the value of mortality risk. J Risk Uncertain 2004 28 : 73 95.
25. Fu T-T, Liu J-T, Hammit JK. Consumer willingness to pay for low-pesticide produce in Taiwan. UK J Agric Econ 1999 50 : 202 233.
26. Liu JT, Hammitt JK. Perceived risk and value of workplace safety in a developing country. J Risk Res 1999 2 : 263 275.
27. Liu J-T, Hammitt JK, Liu J-L. Estimated hedonic wage function and value of life in a developing country. Econ Lett 1997 57 : 353 358.